Patents by Inventor Casey CRAWFORD LYNCH
Casey CRAWFORD LYNCH has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11332464Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.Type: GrantFiled: May 4, 2020Date of Patent: May 17, 2022Assignee: CORTEXYME, INC.Inventors: Andrei W. Konradi, Stephen S. Dominy, Casey Crawford Lynch, Craig Coburn, Joseph Vacca
-
Publication number: 20210017167Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: May 4, 2020Publication date: January 21, 2021Applicant: Cortexyme, Inc.Inventors: Andrei W. Konradi, Stephen S. Dominy, Casey Crawford Lynch, Craig Coburn, Joseph Vacca
-
Patent number: 10676470Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.Type: GrantFiled: April 30, 2019Date of Patent: June 9, 2020Assignee: CORTEXYME, INC.Inventors: Andrei W. Konradi, Stephen S. Dominy, Casey Crawford Lynch, Craig Coburn, Joseph Vacca
-
Publication number: 20190322659Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: April 30, 2019Publication date: October 24, 2019Applicant: Cortexyme, Inc.Inventors: Andrei W. Konradi, Stephen S. Dominy, Casey Crawford Lynch, Craig Coburn, Joseph Vacca
-
Patent number: 10301301Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.Type: GrantFiled: June 4, 2018Date of Patent: May 28, 2019Assignee: CORTEXYME, INC.Inventors: Andrei Konradi, Stephen S. Dominy, Casey Crawford Lynch, Craig Coburn, Joseph Vacca
-
Publication number: 20180346460Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: June 4, 2018Publication date: December 6, 2018Applicant: Cortexyme, Inc.Inventors: Andrei Konradi, Stephen S. Dominy, Casey Crawford Lynch, Craig Coburn, Joseph Vacca
-
Patent number: 9988375Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.Type: GrantFiled: August 22, 2017Date of Patent: June 5, 2018Assignee: CORTEXYME, INC.Inventors: Andrei Konradi, Stephen S. Dominy, Casey Crawford Lynch, Craig Coburn, Joseph Vacca
-
Publication number: 20170349537Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: August 22, 2017Publication date: December 7, 2017Applicant: Cortexyme, Inc.Inventors: Andrei Konradi, Stephen S. Dominy, Casey Crawford Lynch, Craig Coburn, Joseph Vacca
-
Patent number: 9758473Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.Type: GrantFiled: October 5, 2015Date of Patent: September 12, 2017Assignee: CORTEXYME, INC.Inventors: Andrei Konradi, Stephen S. Dominy, Casey Crawford Lynch, Craig Coburn, Joseph Vacca
-
Publication number: 20170014468Abstract: The invention relates to compositions, formulations, vaccines and antibodies for the prevention and/or treatment of aging and brain disorders, including Alzheimer's disease, diabetes, cardiovascular disease, retinal disorders and arthritis. The invention also provides methods of treatment of aging disorders, brain disorders, including Alzheimer's disease, diabetes, cardiovascular disease, retinal disorders, and arthritis by administering compositions, formulations, vaccines and antibodies described in the specification. The invention further provides methods for diagnosing or assessing risk of development of brain disorders in humans and animals. The invention further provides animal models for testing novel therapeutics for brain disorders.Type: ApplicationFiled: April 29, 2015Publication date: January 19, 2017Inventors: Stephen S. Dominy, Casey Crawford Lynch
-
Publication number: 20160096830Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: October 5, 2015Publication date: April 7, 2016Applicant: Cortexyme, Inc.Inventors: Andrei KONRADI, Stephen S. DOMINY, Casey CRAWFORD LYNCH, Craig COBURN, Joseph VACCA